To live or to die: Prosurvival activity of PPARγ in cancers

PPAR Research

Volumn , Issue , 2008, Pages

  Wang, Y Lynn ^a   Miao, Qi ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [1 CARBOXY 2 [4 [2 (5 METHYL 2 PHENYL 4 OXAZOLYL)ETHOXY]PHENYL]ETHYLAMINO]BENZOIC ACID METHYL ESTER; 2 CHLORO 5 NITRO N (4 PYRIDYL)BENZAMIDE; 2 CHLORO 5 NITROBENZANILIDE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; APC PROTEIN; CIGLITAZONE; CYCLOOXYGENASE 2; DELTA12 PROSTAGLANDIN J2; GLITAZONE DERIVATIVE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; SMALL INTERFERING RNA; TROGLITAZONE;

ADENOMATOUS POLYP; ADRENAL CORTEX TUMOR; ANTINEOPLASTIC ACTIVITY; BLADDER CARCINOGENESIS; BREAST ADENOCARCINOMA; BREAST CANCER; CANCER CELL CULTURE; CANCER GROWTH; CANCER INCIDENCE; CANCER MODEL; CANCER PREVENTION; CANCER RISK; CANCER SURVIVAL; CARCINOGENESIS; CARDIOVASCULAR RISK; CELL DEATH; CELL SURVIVAL; CHEMOPROPHYLAXIS; CLINICAL TRIAL; COLON ADENOCARCINOMA; COLON CANCER; CONCENTRATION RESPONSE; DIABETES MELLITUS; DRUG EFFECT; DRUG MECHANISM; EPIDEMIOLOGICAL DATA; FOLLICULAR CARCINOMA; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CARCINOMA; LARGE INTESTINE; LIPOSARCOMA; LIVER CELL CARCINOMA; LIVER TOXICITY; LOW DRUG DOSE; LUNG CANCER; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MAXIMUM PLASMA CONCENTRATION; NEOPLASM; NONHUMAN; OVARY CARCINOMA; PANCREAS ADENOCARCINOMA; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEIN EXPRESSION; RECTUM CARCINOMA; REVIEW; RISK REDUCTION; SIDE EFFECT; SQUAMOUS CELL CARCINOMA; STOMACH ADENOCARCINOMA; THYROID CANCER; THYROID CARCINOMA; TREATMENT RESPONSE;

EID: 53149104358     PISSN: 16874757     EISSN: 16874765     Source Type: Journal    
DOI: 10.1155/2008/209629     Document Type: Review

References (78)

1. Lehmann J. M., Moore L. B., Smith-Oliver T. A., Wilkison W. O., Willson T. M., Kliewer S. A., An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPAR γ) Journal of Biological Chemistry 1995 270 22 12953 12956
2. Rossi A., Kapahi P., Natoli G., Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of I κ B kinase Nature 2000 403 6765 103 108
3. Fuenzalida K. M., Aguilera M. C., Piderit D. G., Peroxisome proliferator-activated receptor γ is a novel target of the nerve growth factor signaling pathway in PC12 cells Journal of Biological Chemistry 2005 280 10 9604 9609
4. Fionda C., Nappi F., Piccoli M., Frati L., Santoni A., Cippitelli M., 15-deoxy- Δ 12, 14 -prostaglandin J 2 negatively regulates rankl gene expression in activated T lymphocytes: role of NF- κ B and early growth response transcription factors Journal of Immunology 2007 178 7 4039 4050
5. Willson T. M., Cobb J. E., Cowan D. J., The structure-activity relationship between peroxisome proliferator-activated receptor γ agonism and the antihyperglycemic activity of thiazolidinediones Journal of Medicinal Chemistry 1996 39 3 665 668
6. Willson T. M., Brown P. J., Sternbach D. D., Henke B. R., The PPARs: from orphan receptors to drug discovery Journal of Medicinal Chemistry 2000 43 4 527 550
7. Kliewer S. A., Lenhard J. M., Willson T. M., Patel I., Morris D. C., Lehmann J. M., A prostaglandin J 2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation Cell 1995 83 5 813 819
8. Harrington E. L., Cox S. R., Determination of ciglitazone in dog plasma by reversed-phase high-performance liquid chromatography Journal of Pharmaceutical and Biomedical Analysis 1985 3 5 483 487
9. Eckland D. A., Danhof M., Clinical pharmacokinetics of pioglitazone Experimental & Clinical Endocrinology and Diabetes 2000 108 supplement 2 S234 S242
10. Young M. A., Lettis S., Eastmond R., Improvement in the gastrointestinal absorption of troglitazone when taken with, or shortly after, food British Journal of Clinical Pharmacology 1998 45 1 31 35
11. Mouihate A., Boissé L., Pittman Q. J., A novel antipyretic action of 15-deoxy- Δ 12, 14 -prostaglandin J 2 in the rat brain Journal of Neuroscience 2004 24 6 1312 1318
12. Bell-Parikh L. C., Ide T., Lawson J. A., McNamara P., Reilly M., FitzGerald G. A., Biosynthesis of 15-deoxy- Δ 12, 14 -PG J 2 and the ligation of PPAR γ Journal of Clinical Investigation 2003 112 6 945 955
13. Segawa Y., Yoshimura R., Hase T., Expression of peroxisome proliferator-activated receptor (PPAR) in human prostate cancer Prostate 2002 51 2 108 116
14. Inoue K., Kawahito Y., Tsubouchi Y., Expression of peroxisome proliferator-activated receptor γ in renal cell carcinoma and growth inhibition by its agonists Biochemical and Biophysical Research Communications 2001 287 3 727 732
15. Keshamouni V. G., Reddy R. C., Arenberg D. A., Peroxisome proliferator-activated receptor- γ activation inhibits tumor progression in non-small-cell lung cancer Oncogene 2004 23 1 100 108
16. Schaefer K. L., Wada K., Takahashi H., Peroxisome proliferator-activated receptor γ inhibition prevents adhesion to the extracellular matrix and induces anoikis in hepatocellular carcinoma cells Cancer Research 2005 65 6 2251 2259
17. Masuda T., Wada K., Nakajima A., Critical role of peroxisome proliferator-activated receptor γ on anoikis and invasion of squamous cell carcinoma Clinical Cancer Research 2005 11 11 4012 4021
18. Elstner E., Müller C., Koshizuka K., Ligands for peroxisome proliferator-activated receptor γ and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice Proceedings of the National Academy of Sciences of the United States of America 1998 95 15 8806 8811
19. Ohta K., Endo T., Haraguchi K., Hershman J. M., Onaya T., Ligands for peroxisome proliferator-activated receptor γ inhibit growth and induce apoptosis of human papillary thyroid carcinoma cells Journal of Clinical Endocrinology & Metabolism 2001 86 5 2170 2177
20. Mueller E., Sarraf P., Tontonoz P., Terminal differentiation of human breast cancer through PPAR γ Molecular Cell 1998 1 3 465 470
21. Zhang G. Y., Ahmed N., Riley C., Enhanced expression of peroxisome proliferator-activated receptor γ in epithelial ovarian carcinoma British Journal of Cancer 2005 92 1 113 119
22. Yoshimura R., Matsuyama M., Segawa Y., Expression of peroxisome proliferator-activated receptors (PPARs) in human urinary bladder carcinoma and growth inhibition by its agonists International Journal of Cancer 2003 104 5 597 602
23. Kristiansen G., Jacob J., Buckendahl A.-C., Peroxisome proliferator-activated receptor γ is highly expressed in pancreatic cancer and is associated with shorter overall survival times Clinical Cancer Research 2006 12 21 6444 6451
24. Sarraf P., Mueller E., Jones D., Differentiation and reversal of malignant changes in colon cancer through PPAR γ Nature Medicine 1998 4 9 1046 1052
25. Sato H., Ishihara S., Kawashima K., Expression of peroxisome proliferator-activated receptor (PPAR) γ in gastric cancer and inhibitory effects of PPAR γ agonists British Journal of Cancer 2000 83 10 1394 1400
26. Tontonoz P., Singer S., Forman B. M., Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor γ and the retinoid X receptor Proceedings of the National Academy of Sciences of the United States of America 1997 94 1 237 241
27. Betz M. J., Shapiro I., Fassnacht M., Peroxisome proliferator-activated receptor- γ agonists suppress adrenocortical tumor cell proliferation and induce differentiation Journal of Clinical Endocrinology & Metabolism 2005 90 7 3886 3896
28. Kroll T. G., Sarraf P., Pecciarini L., PAX8-PPAR γ 1 fusion in oncogene human thyroid carcinoma Science 2000 289 5483 1357 1360
29. Giordano T. J., Au A. Y. M., Kuick R., Delineation, functional validation, and bioinformatic evaluation of gene expression in thyroid follicular carcinomas with the PAX8-PPARG translocation Clinical Cancer Research 2006 12 7 I 1983 1993
30. Chang Y. W., Cho H. L., Jang J. Y., Role of cyclooxygenase-2 (COX-2) and peroxisome proliferator-activated receptor (PPAR) in gastric cancer The Korean Journal of Gastroenterology 2004 43 5 291 298
31. Chinery R., Coffey R. J., Graves-Deal R., Prostaglandin J 2 and 15-deoxy- Δ 12, 14 -prostaglandin J 2 induce proliferation of cyclooxygenase- depleted colorectal cancer cells Cancer Research 1999 59 11 2739 2746
32. Gasparini G., Longo R., Sarmiento R., Morabito A., Inhibitors of cyclo-oxygenase 2: a new class of anticancer agents? The Lancet Oncology 2003 4 10 605 615
33. Sarraf P., Mueller E., Smith W. M., Loss-of-function mutations in PPAR γ associated with human colon cancer Molecular Cell 1999 3 6 799 804
34. Ikezoe T., Miller C. W., Kawano S., Mutational analysis of the peroxisome proliferator-activated receptor γ gene in human malignancies Cancer Research 2001 61 13 5307 5310
35. Jiang J.-G., Johnson C., Zarnegar R., Peroxisome proliferator-activated receptor γ -mediated transcriptional up-regulation of the hepatocyte growth factor gene promoter via a novel composite cis -acting element Journal of Biological Chemistry 2001 276 27 25049 25056
36. Yang C., Jo S.-H., Csernus B., Activation of peroxisome proliferator-activated receptor γ contributes to the survival of T lymphoma cells by affecting cellular metabolism American Journal of Pathology 2007 170 2 722 732
37. Lynn Wang Y., Frauwirth K. A., Rangwala S. M., Lazar M. A., Thompson C. B., Thiazolidinedione activation of peroxisome proliferator-activated receptor γ can enhance mitochondrial potential and promote cell survival Journal of Biological Chemistry 2002 277 35 31781 31788
38. Jo S.-H., Yang C., Miao Q., Peroxisome proliferator-activated receptor γ promotes lymphocyte survival through its actions on cellular metabolic activities Journal of Immunology 2006 177 6 3737 3745
39. Plas D. R., Thompson C. B., Cell metabolism in the regulation of programmed cell death Trends in Endocrinology and Metabolism 2002 13 2 74 78
40. Girnun G. D., Domann F. E., Moore S. A., Robbins M. E. C., Identification of a functional peroxisome proliferator-activated receptor response element in the rat catalase promoter Molecular Endocrinology 2002 16 12 2793 2801
41. Yoo H. Y., Chang M. S., Rho H. M., Induction of the rat Cu/Zn superoxide dismutase gene through the peroxisome proliferator-responsive element by arachidonic acid Gene 1999 234 1 87 91
42. Hwang J., Kleinhenz D. J., Lassègue B., Griendling K. K., Dikalov S., Hart C. M., Peroxisome proliferator-activated receptor- γ ligands regulate endothelial membrane superoxide production American Journal of Physiology 2005 288 4 C899 C905
43. Ferreira-Silva V., Rodrigues A. C., Hirata T. D. C., Hirabara S. M., Curi R., Effects of 15-deoxy- Δ 12, 14 prostaglandin J 2 and ciglitazone on human cancer cell cycle progression and death: the role of PPAR γ European Journal of Pharmacology 2008 580 1-2 80 86
44. Sundararajan S., Gamboa J. L., Victor N. A., Wanderi E. W., Lust W. D., Landreth G. E., Peroxisome proliferator-activated receptor- γ ligands reduce inflammation and infarction size in transient focal ischemia Neuroscience 2005 130 3 685 696
45. Luo Y., Yin W., Signore A. P., Neuroprotection against focal ischemic brain injury by the peroxisome proliferator-activated receptor- γ agonist rosiglitazone Journal of Neurochemistry 2006 97 2 435 448
46. Victor N. A., Wanderi E. W., Gamboa J., Altered PPAR γ expression and activation after transient focal ischemia in rats European Journal of Neuroscience 2006 24 6 1653 1663
47. Tureyen K., Kapadia R., Bowen K. K., Peroxisome proliferator-activated receptor- γ agonists induce neuroprotection following transient focal ischemia in normotensive, normoglycemic as well as hypertensive and type-2 diabetic rodents Journal of Neurochemistry 2007 101 1 41 56
48. Wayman N. S., Hattori Y., McDonald M. C., Ligands of the peroxisome proliferator-activated receptors (PPAR- γ and PPAR- α) reduce myocardial infarct size The FASEB Journal 2002 16 9 1027 1040
49. Ito H., Nakano A., Kinoshita M., Matsumori A., Pioglitazone, a peroxisome proliferator-activated receptor- γ agonist, attenuates myocardial ischemia/reperfusion injury in a rat model Laboratory Investigation 2003 83 12 1715 1721
50. Liu H.-R., Tao L., Gao E., Anti-apoptotic effects of rosiglitazone in hypercholesterolemic rabbits subjected to myocardial ischemia and reperfusion Cardiovascular Research 2004 62 1 135 144
51. Sivarajah A., Chatterjee P. K., Patel N. S. A., Agonists of peroxisome-proliferator activated receptor- γ reduce renal ischemia/reperfusion injury American Journal of Nephrology 2003 23 4 267 276
52. Kapadia R., Yi J.-H., Vemuganti R., Mechanisms of anti-inflammatory and neuroprotective actions of PPAR- γ agonists Frontiers in Bioscience 2008 13 5 1813 1826
53. Dang C. V., Semenza G. L., Oncogenic alterations of metabolism Trends in Biochemical Sciences 1999 24 2 68 72
54. Izuishi K., Kato K., Ogura T., Kinoshita T., Esumi H., Remarkable tolerance of tumor cells to nutrient deprivation: possible new biochemical target for cancer therapy Cancer Research 2000 60 21 6201 6207
55. Lefebvre A.-M., Chen I., Desreumaux P., Activation of the peroxisome proliferator-activated receptor γ promotes the development of colon tumors in C57BL/6J- APC M i n / + mice Nature Medicine 1998 4 9 1053 1057
56. Saez E., Tontonoz P., Nelson M. C., Activators of the nuclear receptor PPAR γ enhance colon polyp formation Nature Medicine 1998 4 9 1058 1061
57. Girnun G. D., Smith W. M., Drori S., APC-dependent suppression of colon carcinogenesis by PPAR γ Proceedings of the National Academy of Sciences of the United States of America 2002 99 21 13771 13776
58. Yang K., Fan K.-H., Lamprecht S. A., Peroxisome proliferator-activated receptor γ agonist troglitazone induces colon tumors in normal C57BL/6J mice and enhances colonic carcinogenesis in A p c 1638 N / + M l h 1 + /-double mutant mice International Journal of Cancer 2005 116 4 495 499
59. Osawa E., Nakajima A., Wada K., Peroxisome proliferator-activated receptor γ ligands suppress colon carcinogenesis induced by azoxymethane in mice Gastroenterology 2003 124 2 361 367
60. Saez E., Rosenfeld J., Livolsi A., PPAR γ signaling exacerbates mammary gland tumor development Genes & Development 2004 18 5 528 540
61. Suh N., Wang Y., Williams C. R., A new ligand for the peroxisome proliferator-activated receptor- γ (PPAR- γ), GW7845, inhibits rat mammary carcinogenesis Cancer Research 1999 59 22 5671 5673
62. Nicol C. J., Yoon M., Ward J. M., PPAR γ influences susceptibility to DMBA-induced mammary, ovarian and skin carcinogenesis Carcinogenesis 2004 25 9 1747 1755
63. Cui Y., Miyoshi K., Claudio E., Loss of the peroxisome proliferation-activated receptor γ (PPAR γ) does not affect mammary development and propensity for tumor formation but leads to reduced fertility Journal of Biological Chemistry 2002 277 20 17830 17835
64. Saez E., Olson P., Evans R. M., Genetic deficiency in Pparg does not alter development of experimental prostate cancer Nature Medicine 2003 9 10 1265 1266
65. Kato Y., Ying H., Zhao L., PPAR γ insufficiency promotes follicular thyroid carcinogenesis via activation of the nuclear factor- κ B signaling pathway Oncogene 2006 25 19 2736 2747
66. Lu J., Imamura K., Nomura S., Chemopreventive effect of peroxisome proliferator-activated receptor γ on gastric carcinogenesis in mice Cancer Research 2005 65 11 4769 4774
67. Bren-Mattison Y., Meyer A. M., Van Putten V., Antitumorigenic effects of peroxisome proliferator-activated receptor- γ in non-small-cell lung cancer cells are mediated by suppression of cyclooxygenase-2 via inhibition of nuclear factor- κ B Molecular Pharmacology 2008 73 3 709 717
68. Debrock G., Vanhentenrijk V., Sciot R., Debiec-Rychter M., Oyen R., Van Oosterom A., A phase II trial with rosiglitazone in liposarcoma patients British Journal of Cancer 2003 89 8 1409 1412
69. Kebebew E., Peng M., Reiff E., A phase II trial of rosiglitazone in patients with thyroglobulin-positive and radioiodine-negative differentiated thyroid cancer Surgery 2006 140 6 960 967
70. Kulke M. H., Demetri G. D., Sharpless N. E., A phase II study of troglitazone, an activator of the PPAR γ receptor, in patients with chemotherapy-resistant metastatic colorectal cancer Cancer Journal 2002 8 5 395 399
71. Burstein H. J., Demetri G. D., Mueller E., Sarraf P., Spiegelman B. M., Winer E. P., Use of the peroxisome proliferator-activated receptor (PPAR) γ ligand troglitazone as treatment for refractory breast cancer: a phase II study Breast Cancer Research and Treatment 2003 79 3 391 397
72. Yee L. D., Williams N., Wen P., Pilot study of rosiglitazone therapy in women with breast cancer: effects of short-term therapy on tumor tissue and serum markers Clinical Cancer Research 2007 13 1 246 252
73. Mueller E., Smith M., Sarraf P., Effects of ligand activation of peroxisome proliferator-activated receptor γ in human prostate cancer Proceedings of the National Academy of Sciences of the United States of America 2000 97 20 10990 10995
74. Smith M. R., Manola J., Kaufman D. S., Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate-specific antigen level after radical prostatectomy and/or radiation therapy Cancer 2004 101 7 1569 1574
75. Nissen S. E., Wolski K., Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes The New England Journal of Medicine 2007 356 24 2457 2471
76. Home P. D., Pocock S. J., Beck-Nielsen H., Rosiglitazone evaluated for cardiovascular outcomes-an interim analysis The New England Journal of Medicine 2007 357 1 28 38
77. Govindarajan R., Ratnasinghe L., Simmons D. L., Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes Journal of Clinical Oncology 2007 25 12 1476 1481
78. Rosen C. J., The rosiglitazone story-lessons from an FDA advisory committee meeting The New England Journal of Medicine 2007 357 9 844 846